Clinical Trials Browser

atezolizumab × Dermatologic × 1 year × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06066138 2026-03-11

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

30 enrolled

DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

20 enrolled

Dermatologic

Melanoma

NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

450 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

51 enrolled

Dermatologic

Melanoma

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT06332755 2025-11-24

LB-LR1109

Phase 1 Recruiting

76 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT03175432 2025-11-03

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT04273061 2025-09-22

CAPTIV-8

Phase 2 Recruiting

200 enrolled

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Sarcoma, Skin Neoplasms, Urogenital Neoplasms

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 2 FDA

Dermatologic

Melanoma

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1/2 Completed

110 enrolled 27 charts

Dermatologic

Melanoma

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

272 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04356729 2025-06-29

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

30 enrolled

Dermatologic

Melanoma

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

186 enrolled

Dermatologic

Melanoma

NCT05483400 2025-03-30

TIRACAN

Phase 2 Recruiting

97 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Neoadjuvant Atezolizumab in Cutaneous Melanoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

LB-LR1109

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

CAPTIV-8

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

ImmunoCobiVem

TIRACAN